Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UNF1
UPID:
MAGD2_HUMAN
Alternative names:
11B6; Breast cancer-associated gene 1 protein; Hepatocellular carcinoma-associated protein JCL-1; MAGE-D2 antigen
Alternative UPACC:
Q9UNF1; A6NMX0; O76058; Q5BJF3; Q8NAL6; Q9H218; Q9P0U9; Q9UM52
Background:
Melanoma-associated antigen D2 (MAGE-D2), also known by alternative names such as 11B6, Breast cancer-associated gene 1 protein, Hepatocellular carcinoma-associated protein JCL-1, and MAGE-D2 antigen, plays a crucial role in the body's salt balance. It regulates the expression, localization to the plasma membrane, and function of sodium chloride cotransporters SLC12A1 and SLC12A3, essential for salt reabsorption in the distal renal tubule.
Therapeutic significance:
MAGE-D2's involvement in Bartter syndrome 5, an antenatal, transient form characterized by impaired salt reabsorption, highlights its potential as a target for therapeutic intervention. Understanding the role of MAGE-D2 could open doors to potential therapeutic strategies for managing this condition.